Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is a leading medical device company specializing in the design, development, and commercialization of innovative insulin pump technology for individuals with insulin-dependent diabetes. Despite facing stiff competition from industry giants like Medtronic and Insulet Corporation, Tandem continues to make strides in the diabetes care market.

On December 17, 2025, RBC Capital maintained its "Outperform" rating for Tandem Diabetes, highlighting a positive outlook for the company with the stock priced at $22.60. RBC Capital also raised its price target from $25 to $30, signaling confidence in Tandem's growth potential. This optimistic stance contrasts with the average "Hold" recommendation from seventeen analysts covering TNDM, as reported by Defense World.

Analyst ratings for Tandem Diabetes Care show a mixed sentiment, with one analyst issuing a "sell" rating, eleven recommending a "hold", and five supporting a "buy" rating. The average twelve-month price target set by brokerages stands at approximately $22.44, slightly below the current stock price of $23.03. This indicates a modest increase of 1.90% or $0.43.

Notably, Stifel Nicolaus initiated coverage on Tandem Diabetes Care with a "hold" rating and a target price of $15.00. Canaccord Genuity Group reaffirmed their "buy" rating with a price objective of $24.00, while Robert W. Baird echoed RBC Capital's positive outlook with an "outperform" rating and a target price of $30.00.

The stock has experienced fluctuations, trading between a low of $22.40 and a high of $23.10 during the day. Over the past year, TNDM's stock reached a peak of $38.28 and a low of $9.98. With a market capitalization of approximately $1.56 billion and a trading volume of 120,728 shares on the NASDAQ exchange, Tandem Diabetes Care remains a significant player in the diabetes care industry.